Research programme: voltage-gated sodium channel inhibitors - Merck

Drug Profile

Research programme: voltage-gated sodium channel inhibitors - Merck

Latest Information Update: 02 Sep 2010

Price : $50

At a glance

  • Originator Merck & Co
  • Class Amides; Biphenyl compounds; Pyrazoles
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Neuropathic pain

Most Recent Events

  • 26 Aug 2010 Pharmacodynamics and pharmacokinetics data from preclinical studies in rodents presented at the 240th American Society National Meeting (240th-ACS-2010)
  • 05 Sep 2007 Preclinical data presented at the 234th American Chemical Society National Meeting (234th-ACS-2007) added to the pharmacokinetics section
  • 10 Apr 2007 Preclinical trials in Neuropathic pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top